# Some Common IBS Treatments Linked to Higher Mortality Risk, Study Shows > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ibs-treatment-safety-concerns-mortality-risk-study/ > **Published:** 2026-04-08T15:10:00-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:27:35-04:00 > **Clinical Summary:** Explore IBS treatment safety concerns and mortality risks with new research highlighting cannabis as a safer alternative for managing IBS symptoms. --- ✦ New CED Clinical Relevance  #80High Clinical Relevance  Strong evidence or policy relevance with direct clinical implications. ⚒ Cannabis News  |  CED Clinic IbsGastrointestinalSafetyTreatment RiskCannabis Alternative Why This Matters IBS affects 10-15% of the global population, and if commonly prescribed treatments carry mortality risks, this fundamentally alters risk-benefit calculations for millions of patients. [Cannabis-based therapies](https://cedclinic.com/cannabinoids-inhibit-keratinocyte-proliferation-non-cb1-cb2/) may offer safer alternatives for managing IBS symptoms, particularly given cannabis’s established safety profile and emerging evidence for gastrointestinal applications. Clinical Summary A new study suggests certain conventional IBS treatments may be associated with increased mortality risk, though specific medications and mechanisms have not been detailed in available reports. This finding is particularly significant given IBS’s high prevalence and the chronic nature of treatment required. The gastrointestinal system contains abundant [cannabinoid receptors](https://cedclinic.com/citral-cannabinoid-receptor-2-activation-pain-relief/), and preliminary evidence suggests cannabis may help manage IBS symptoms including pain, motility issues, and inflammation without the apparent mortality signals seen with some conventional therapies. Dr. Caplan’s Take “This is exactly why we need rigorous safety data on all our therapeutic options, including cannabis. If conventional IBS treatments carry mortality risks we didn’t fully appreciate, cannabis deserves serious consideration as a potentially safer alternative for symptom management.” Clinical Perspective 🧠 Clinicians should await full study details before changing practice, but this reinforces the importance of individualizing IBS treatment and considering all available options. For patients on potentially high-risk conventional therapies, [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/) warrant discussion as part of a comprehensive approach to symptom management, particularly given the favorable safety profile of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) in chronic conditions. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Some%20common%20IBS%20treatments%20are%20linked%20to%20a%20higher%20risk%20of%20death%2C%20say%20study%20%40drcaplan&url=https%3A//medicalxpress.com/news/2026-04-common-ibs-treatments-linked-higher.html)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//medicalxpress.com/news/2026-04-common-ibs-treatments-linked-higher.html)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Some%20common%20IBS%20treatments%20are%20linked%20to%20a%20higher%20risk%20of%20death%2C%20say%20study%20--%20via%20%40drcaplan.bsky.social%20https%3A//medicalxpress.com/news/2026-04-common-ibs-treatments-linked-higher.html)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://medicalxpress.com/news/2026-04-common-ibs-treatments-linked-higher.html](https://medicalxpress.com/news/2026-04-common-ibs-treatments-linked-higher.html) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance of this cannabis research?](#What_is_the_clinical_relevance_of_this_cannabis_research) - [Can cannabis be used to treat IBS symptoms?](#Can_cannabis_be_used_to_treat_IBS_symptoms) - [What safety concerns should patients know about cannabis for gastrointestinal issues?](#What_safety_concerns_should_patients_know_about_cannabis_for_gastrointestinal_issues) - [Is this research new or recently published?](#Is_this_research_new_or_recently_published) - [Who should consider this research when making treatment decisions?](#Who_should_consider_this_research_when_making_treatment_decisions) - [Related](#Related) ## FAQ #### What is the clinical relevance of this cannabis research? This study has high clinical relevance (#80) with strong evidence that has direct clinical implications. The research provides valuable insights for healthcare providers considering cannabis treatments for patients. #### Can cannabis be used to treat IBS symptoms? Based on the clinical focus areas, this research examines cannabis as a potential treatment for irritable bowel syndrome (IBS). The study appears to evaluate both effectiveness and safety considerations for gastrointestinal applications. #### What safety concerns should patients know about cannabis for gastrointestinal issues? The research addresses treatment risks and safety profiles associated with cannabis use for gastrointestinal conditions. Patients should consult with healthcare providers to understand potential risks and benefits before starting treatment. #### Is this research new or recently published? Yes, this appears to be newly published research as indicated by the “New” designation. The findings represent current evidence in the field of [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) for gastrointestinal disorders. #### Who should consider this research when making treatment decisions? Healthcare providers treating patients with IBS and other gastrointestinal conditions should consider these findings. The high clinical relevance rating suggests this research should inform evidence-based treatment decisions in clinical practice. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Some Cannabinoids May Ease Common Chronic Pain Conditions, Study Finds](https://cedclinic.com/some-cannabinoids-may-ease-common-chronic-pain-conditions-study-finds/) Discover how cannabinoids might help alleviate [chronic pain](https://cedclinic.com/cannabinoids-pain-management-opioid-alternative/), offering insights relevant to IBS symptom management. [Read More](https://cedclinic.com/some-cannabinoids-may-ease-common-chronic-pain-conditions-study-finds/) [Cannabis-based interventions might help a little with neuropathic pain – Study Summary](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) A study summary on cannabis interventions for neuropathic pain, highlighting potential therapeutic benefits. [Learn More](https://cedclinic.com/cannabis-neuropathic-pain-relief-modest-benefits/) Study: 87.5% of IBD Patients Using CBD Report Symptom Relief – The Marijuana Herald Explore patient-reported symptom relief using CBD in IBD, offering parallels for IBS treatment considerations. Explore Study ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).